Article

Combination of NY-ESO-1-TCR-T-cells coengineered to secrete SiRPα decoys with anti-tumor antibodies to augment macrophage phagocytosis

2023-06-29

Abstract excerpt

<h4>ABSTRACT</h4> The adoptive transfer of T cell receptor (TCR)-engineered T cells (ACT) targeting the HLA-A2 restricted cancer-testis epitope NY-ESO-1 157-165 (A2/NY) has yielded favorable clinical responses against a variety of cancers. Two promising approaches to improve ACT efficacy are TCR affinity-optimization and combinatorial treatment strategies to reprogram the tumor microenvironment (TME). By computa...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 8617169a-1ed1-5621-b4b3-6442d468d118
DOI: 10.1101/2023.06.27.546523

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Combination of NY-ESO-1-TCR-T-cells coengineered to secrete SiRPα decoys with anti-tumor antibodies to augment macrophage phagocytosisDOI 10.1101/2023.06.27.546523Read

Development of an affinity-enhanced clinical candidate TCR targeting NY-ESO-1 with optimal potency and high specificitySemantic proximity Read

A CD8αβ co-receptor modified to contain an intracellular CD28 signaling tail enhances TCR-engineered T cell function independent of solid-tumor-associated co-stimulatory ligandsSemantic proximity Read

OPS-γδ: allogeneic opsonin-secreting γδT cell immunotherapy for solid tumours mediates direct and bystander immunitySemantic proximity Read

Engineering chimeric antigen receptor-T cells for cancer treatment.Semantic proximity Read

Effective NY-ESO-1–specific MHC II–restricted T cell receptors from antigen-negative hosts enhance tumor regressionSemantic proximity Read

CAR macrophages with built-In CD47 blocker combat tumor antigen heterogeneity and activate T cells via cross-presentationSemantic proximity Read

Engineered CD4 TCR T cells with conserved high-affinity TCRs targeting NY-ESO-1 for advanced cellular therapies in cancerSemantic proximity Read

PD-L1 blockade restores CAR T cell activity through IFNγ-regulation of CD163+ macrophagesSemantic proximity Read

Adoptive cell therapy using T cell receptors equipped with ICOS yields durable anti-tumor responseSemantic proximity Read

A rare population of tumor antigen-specific CD4+CD8+ double-positive αβ T lymphocytes uniquely provide CD8-independent TCR genes for engineering therapeutic T cellsSemantic proximity Read

Targeting PD-L1 in solid cancer with myeloid cells expressing a CAR-like immune receptorSemantic proximity Read

Development of a CD8 co-receptor independent T-cell receptor specific for tumor-associated antigen MAGE-A4 for next generation T-cell-based immunotherapy.Semantic proximity Read